- Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Thursday, the FDA approved Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under accelerated approval based on the overall response rat
- Insider Monkey
Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
We recently compiled a list of the 10 Best One-Dollar Stocks To Buy Now. In this article, we are going to take a look at where Adaptimmune Therapeutics plc (NASDAQ:ADAP) stands against the other one-dollar stocks. The upward trend in the stock market has resumed, supported by strong first-quarter and second-quarter results that have relieved […]
- InvestorPlace
3 Biotech Moonshots With Imminent Catalyst Potential
For most of the year, biotech has been one of the most explosive sectors on the market. Far from over, further upside is likely, thanks to some of the top biotech stocks with catalysts. Look at the iShares Nasdaq Biotech ETF (NASDAQ:IBB), for example. Since last year, the ETF ran from a low of about $110 to a high of $140. Even the SPDR S&P Biotech ETF (NYSEARCA:XBI) popped from a low of about $65 to a high of $91.36. All thanks to newer innovation, demand for better treatment, pharmaceutical co
